Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology company whose news flow reflects activity across medical discovery, diagnostics, drug delivery and interventional care. On this page, readers can follow company-issued updates and third-party coverage related to BD’s operations, product clearances, collaborations and corporate developments.
Recent BD news highlights regulatory milestones, such as U.S. FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy platform designed to support early detection and diagnosis of breast disease. Other announcements showcase BD’s role in supporting the pharmaceutical supply chain, including investments to expand production of BD Neopak™ Glass Prefillable Syringes in the United States to help meet growing demand for biologic and GLP-1 drug delivery.
Investors and observers can also track BD’s clinical and surgical innovations, including milestones with Phasix™ Mesh for hernia prevention in Europe and progress in the PREVENT trial, as well as the European launch of the BD Surgiphor™ Surgical Wound Irrigation System. In diagnostics and research, BD reports collaborations with institutions such as the University of Pennsylvania’s Institute for Immunology and Immune Health, and product updates like new IVDR-certified VIASURE assays for the BD MAX™ System and expanded configurations of BD FACSDiscover™ A8 Cell Analyzers.
Corporate governance and financial communications feature in BD’s news as well, with items such as leadership appointments in investor relations and notices regarding annual shareholder meetings. This news feed offers a centralized view of BD’s product pipeline, strategic investments, partnerships and regulatory events, providing context for how the company positions itself within the medical technology landscape.
BD (Becton, Dickinson and Company) has appointed Elizabeth McCombs as executive vice president and chief technology officer, effective April 26, 2021. McCombs, with over 20 years of experience in medical device innovation, previously led R&D for BD's Medical Segment. Her role will focus on driving the company's innovation strategy and managing R&D efforts. Additionally, BD has established a new Scientific Advisory Board to enhance its innovation pipeline, with John DeFord as co-chair following his retirement on May 28, 2021.
The Board of Directors of BD (Becton, Dickinson and Company) has announced a quarterly dividend of $0.83 per common share, payable on June 30, 2021 to shareholders on record as of June 9, 2021. This indicates an annual dividend rate of $3.32 per share, reflecting the company's commitment to returning value to its investors.
On April 27, 2021, CerTest Biotec and BD (Becton, Dickinson and Company) announced that the VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR Detection Kit can now detect COVID-19 using saliva specimens on the BD MAX™ Molecular Diagnostic System. This addition enhances testing flexibility, allowing for nasopharyngeal, oropharyngeal, and saliva sample collection. The kit is CE marked and capable of detecting all known SARS-CoV-2 variants, essential for managing the ongoing pandemic in Europe.
BD (Becton, Dickinson and Company) has submitted a 510(k) premarket notification to the U.S. FDA for its BD Alaris™ System, a widely used infusion pump in U.S. hospitals. The submission aims to update regulatory clearance, implement new features, and address existing recall issues. The new software version will enhance clinical, operational, and cybersecurity aspects. BD emphasizes this submission as a pivotal step in their commitment to healthcare improvement. However, the FDA review process includes risks and there is no guarantee of clearance or specific timing.
BD (Becton, Dickinson and Company) has partnered with USA Track & Field (USATF) to implement rapid COVID-19 testing for athletes at the Journey to Gold events. Utilizing the BD Veritor™ Plus system, tests will be administered to ensure athlete safety as they prepare for the U.S. Olympic Trials. The testing program includes administering tests every two days, exceeding U.S. Olympic Committee guidelines. To date, 410 tests have been conducted with two positive results. This initiative aligns with BD's commitment to supporting safe return to competition and community health.
Summary not available.
BD (Becton, Dickinson and Company) is voluntarily recalling specific lots of the ChloraPrep™ Hi-Lite Orange™ 26 mL Applicator due to a manufacturing defect that can lead to broken glass and solution release. The recall affects products distributed in the United States and Puerto Rico. While no severe injuries have been reported, potential risks include superficial to deep lacerations and possible infection. BD has received 56 complaints, with one incident of laceration. The company is notifying affected customers and providing disposal instructions.
BD (Becton, Dickinson and Company) has announced a commitment of $1 million over five years to support UNICEF USA's initiatives targeting the elimination of Maternal and Neonatal Tetanus (MNT) in at-risk countries. This donation builds on BD's ongoing partnership, contributing over $10.8 million to UNICEF's efforts since 1997. The initiative aims to vaccinate women and promote safe childbirth practices, addressing a disease that claims a newborn every 21 minutes. BD continues to advocate for healthcare access among vulnerable populations.
Vicarious Surgical Inc. and D8 Holdings Corp. have reached a definitive business combination agreement, transitioning Vicarious to publicly trade under the new ticker symbol RBOT post-closing on the NYSE. This merger aims to enhance surgical efficiency and patient outcomes through Vicarious's advanced robotics technology, which provides significant cost savings compared to legacy systems. The transaction could yield up to $460 million in gross proceeds, supported by a $115 million private placement. The merger is anticipated to finalize by Q3 2021, pending D8 shareholder approval.
BD (Becton, Dickinson and Company) announced it has received 510(k) clearance from the FDA for its new Pristine™ Long-Term Hemodialysis Catheter, set to be available in the U.S. in May 2021. This innovative catheter features a unique side-hole free symmetric Y-Tip™ distal lumen design aimed at improving patient outcomes by minimizing complications such as thrombus formation. Following a feasibility study involving 45 patients, primary patency rates were reported at 100.0% at 60 days and 90.9% at 180 days, indicating promising performance for patients requiring hemodialysis.